# US 2022/0034911 A1 · Method of mitigation of death from epileptic seizures

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0034911 A1
- Document ID: US20220034911A1
- Status: Published application
- Kind: A1
- Application number: 16/965,994
- Filed: 2019-09-09
- Published: 2022-02-03
- Earliest claimed: 2018-09-10
- Inventors: Jose VEGA
- Web page: https://patentgrep.com/patent/US20220034911A1

## CPC

- A61B 5/14507: {specially adapted for measuring characteristics of body fluids other than blood (devices for taking samples of body liquids A61B10/0045)}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61B 5/024: Measuring pulse rate or heart rate
- A61B 5/08: Measuring devices for evaluating the respiratory organs
- A61B 5/4035: {Evaluating the autonomic nervous system}
- A61B 5/4094: {Diagnosing or monitoring seizure diseases, e.g. epilepsy}
- A61B 5/7275: {Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor}
- A61B 10/0051: {for taking saliva or sputum samples (devices for receiving spittle A61J9/00)}
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61B 5/0826: {Detecting or evaluating apnoea events (sleep apnoea A61B5/4818)}
- A61B 5/14539: {for measuring pH}
- A61B 5/14551: {for measuring blood gases}
- G01N 2800/2857: Seizure disorders; Epilepsy
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for determining the severity of a mammalian dive response (MDR) triggered during a patient's seizure that includes the following steps: (1) collecting an ictal specimen, the ictal specimen being a saliva or any other secretion from the mouth of the patient when the patient is in a peri-ictal period; (2) analyzing the ictal specimen to measure a level of a specimen marker, the specimen marker being a cellular or non-cellular biological component; and (3) determining the severity of the MDR or other autonomic reflex based on the level of the specimen marker.

## Claims

### Claim 1

A method for determining the severity of a mammalian dive response (MDR) triggered during a patient's seizure comprising the following steps:
(1) collecting an ictal specimen, the ictal specimen being a saliva or any other secretion from the nose or mouth of the patient when the patient is in a peri-ictal period;
(2) analyzing the ictal specimen to measure a level of a specimen marker, the specimen marker being a cellular or non-cellular biological component; and
(3) determining the severity of the MDR based on the level of the specimen marker.

### Claim 2 (depends on 1)

The method of claim 1, wherein step (2) comprises
collecting a reference specimen, the reference specimen being a saliva or any other secretion from the nose or mouth of the patient when the patient is not having a seizure or from a pool of healthy age-appropriate seizure-free volunteers; and
analyzing the ictal specimen to measure the level of the specimen marker;
analyzing the reference specimen to measure a level of the specimen marker; and
comparing the level of the specimen marker in the ictal specimen with the level of the specimen marker in the reference specimen.

### Claim 3 (depends on 2)

The method of claim 2, wherein the ictal specimen and the reference specimen are a tissue, a fluid, a cell, an electrolyte, or a molecule found in or around a respiratory system.

### Claim 4 (depends on 3)

The method of claim 3, wherein the ictal specimen and reference specimen are a cell that makes up an oro-nasal cavity, a pharyngeal cavity, or a lung parenchyma; a cell that makes up lung blood vessels; a molecule that makes up connective tissues of lungs and tracheobronchial tree; an electrolyte or a cell or platelet that circulates throughout a lung, peritracheal, peri-bronchial arteries, veins or lymphatic vessels; or an electrolyte or a molecule, cell or fluid that makes up or that extravasates into lung alveoli, or into the lumen of tracheobronchial tree.

### Claim 5 (depends on 2)

The method of claim 2, wherein the ictal specimen and reference specimen are a biological component that enters a lung through pulmonary arteries.

### Claim 6 (depends on 1)

The method of claim 1, wherein the specimen marker is selected from the group consisting of electrolytes, carbohydrates, proteins, lipids, and nucleic acids; or the specimen marker is a surfactant.

### Claim 7

(canceled)

### Claim 8 (depends on 2)

The method of claim 2, wherein step (3) comprises:
determining that the severity of the MDR is high and a prophylactic pharmacological approach is required when the level of the specimen marker in the ictal specimen is 2 times, 5 times, or 10 times higher than the level of the specimen marker in the reference specimen.

### Claim 9 (depends on 8)

The method of claim 8, wherein the prophylactic pharmacological approach is to administer to the patient an adrenergic blocking agent selected from the group consisting of n-g(fluorenyl)-n ethyl-β chloroethylamine (SKF-501), Phentolamine, Doxazosin, Terazosin, Tamsulosin, Alfuzosin, Phenoxybenzaamine, Yohimbine, Imipramine, Silodosin, Amitriptilyne, Indoramine, Abanoquil, Corynanthine, Ajmalicine, Quetiapine, Dapiprazone, Amoxapine, Risperidone, Idazoxan, Bunazosin, Doxepin, Atiprosin, Piperoxan, Fenmetozole, Denopamine, Dobutamine, Dopexamine, Epinephrine, Isoprenaline, Isoproterenol, Prenalterol, Xamotero, Arformoterol, Buphenine, Clenbuterol, Dopexamine, Fenoterol, Formoterol, Isoetarine, Levosalbutamol, levalbuterol, Orciprenaline, metaproterenol, Pirbuterol, Procaterol, Ritodrine, Salbutamol, albuterol, Salmeterol, Terbutaline, Arbutamine, Befunolol, Bromoacetylalprenololmenthane, Broxaterol, Cimaterol, Cirazoline, Etilefrine, Hexoprenaline, Higenamine, Isoxsuprine, Mabuterol, Methoxyphenamine, Oxyfedrine, Ractopamine, Reproterol, Rimiterol, Tretoquinol, Tulobuterol, Zilpaterol, Zinterol, Propranolol, Bucindolol, Carteolol, Carvedilol, Labetalol, Nadolol, Oxprenolol, Penbutolol, Pindolol, Sotalol, Timolol, Acebutolol, Atenolol, Betaxolol, Bisoprolol, Celiprolol, Metoprolol, Nebivolol, Esmolol, Butaxamine, ICI-118,551, SR 59230A, 4-NEMD, 7-Me-marsanidine, Agmatine, Apraclonidine, Brimonidine, Cannabigerol, Clonidine, Detomidine, Dexmedetomidine, Fadolmidine, Guanabenz, Guanfacine, Lofexidine, Marsanidine, Medetomidine, Methamphetamine, Mivazerol, Rilmenidine, Romifidine, Talipexole, Tiamenidine, Tizanidine, Tolonidine, Xylazine, Xylometazoline, L-748,328, L-748,337 and SR 59,230A, Amibegron (SR-58611A), CL-316,243, L-742,791, L-796,568, LY-368,842, Mirabegron (YM-178), Ro40-2148, Solabegron (GW-427,353), and Vibegron (MK-4618); or to administer to the patient a sympathetic ganglionic blocking agent selected from the group consisting of hexamethonium, pentolinium, mecamylamine, trimetaphan, tubocurarine, pempidine, benzohexonium, chlorisondamine, pentamine, and tetra ethylammonium chloride; or to administer to the patient a cholinergic receptor blocking agent selected from the group consisting of atropine, scopolamine, homatropine, tropicamide, benzproine, biperiden, trihexyphenidyl, oxybutynin, tolterodine, solifenacin, dicyclomine, darifenacin, glycopyrrolate, ipratropium, and tiotropium; or to administer the patient with a combination thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein step (2) comprises an analysis selected from a group consisting of mass spectrometry, protein profile analysis, protein chip array analysis, lipid profile analysis, nucleic acid profile analysis, and immunofluorescence.

### Claim 11 (depends on 1)

The method of claim 1, wherein the ictal specimen and the reference specimen are measured by a portable sample analyzing unit.

### Claim 12

A method for determining the severity of a mammalian dive response (MDR) or similar autonomic reflex triggered during a seizure comprising the following steps:
(1) collecting an ictal blood sample from a patient when the patient is in a peri-ictal period;
(2) analyzing the ictal blood sample for the levels of one or more blood markers;
(3) collecting a reference blood sample from the patient when the patient is not having a seizure;
(4) analyzing the reference blood sample for the levels of the one or more blood markers; and
(5) comparing the levels of the one or more blood markers in the ictal blood sample and the levels of the one or more blood markers in the reference blood sample.

### Claim 13 (depends on 12)

The method of claim 12, wherein the one or more blood markers are selected from the group consisting of electrolytes, carbohydrates, proteins, lipids, nucleic acids, cell surface molecules, a human body tissue (e.g., lungs, muscles, liver, spleen, intestines, bone marrow, arteries, veins, etc.), white blood cells, red blood cells, platelets, pH, lactic acid level, carbon dioxide level, oxygen level, and blood oxygen saturation level.

### Claim 14 (depends on 12)

The method of claim 12, further comprising:
measuring the patient's pulse.

### Claim 15 (depends on 13)

The method of claim 13, further comprising:
determining that the severity of the MDR triggered during a seizure is severe and a prophylactic pharmacological approach is required when the levels of the one or more blood markers in the ictal blood sample are 2 times, 5 times, or 10 times than the levels of the one or more blood markers in the reference blood sample.

### Claim 16 (depends on 13)

The method of claim 13, further comprising:
determining that the severity of the MDR triggered during a seizure is severe and a prophylactic pharmacological approach is required when the levels of the one or more blood markers in the ictal blood sample are 3%, 5%, or 10% lower than the levels of the one or more blood markers in the reference blood sample, wherein the one or more blood markers are pH or oxygen level.

### Claim 17 (depends on 12)

The method of claim 12, further comprising:
determining that the severity of the MDR triggered during a seizure is high and a prophylactic pharmacological approach is required when the blood white cell count in the ictal blood sample is higher than 9,200 cells/mm3, 16,000 cells/mm3, 18,000 cells/mm3, 20,000 cells/mm3, 22,000 cells/mm3, 24,000 cells/mm3, 26,000 cells/mm3, 28,000 cells/mm3, 30,000 cells/mm3, or 32,000 cells/mm3, wherein the one or more blood markers are blood white cell.

### Claim 18 (depends on 12)

The method of claim 12, wherein the ictal blood sample and reference blood sample are measured by a portable sample analyzing unit.

### Claim 19 (depends on 15)

The method of claim 15, wherein the prophylactic pharmacological approach is to administer to the patient an adrenergic blocking agent selected from the group consisting of n-g(fluorenyl)-n ethyl-β chloroethylamine (SKF-501), Phentolamine, Doxazosin, Terazosin, Tamsulosin, Alfuzosin, Phenoxybenzaamine, Yohimbine, Imipramine, Silodosin, Amitriptilyne, Indoramine, Abanoquil, Corynanthine, Ajmalicine, Quetiapine, Dapiprazone, Amoxapine, Risperidone, Idazoxan, Bunazosin, Doxepin, Atiprosin, Piperoxan, Fenmetozole, Denopamine, Dobutamine, Dopexamine, Epinephrine, Isoprenaline, Isoproterenol, Prenalterol, Xamotero, Arformoterol, Buphenine, Clenbuterol, Dopexamine, Fenoterol, Formoterol, Isoetarine, Levosalbutamol, levalbuterol, Orciprenaline, metaproterenol, Pirbuterol, Procaterol, Ritodrine, Salbutamol, albuterol, Salmeterol, Terbutaline, Arbutamine, Befunolol, Bromoacetylalprenololmenthane, Broxaterol, Cimaterol, Cirazoline, Etilefrine, Hexoprenaline, Higenamine, Isoxsuprine, Mabuterol, Methoxyphenamine, Oxyfedrine, Ractopamine, Reproterol, Rimiterol, Tretoquinol, Tulobuterol, Zilpaterol, Zinterol, Propranolol, Bucindolol, Carteolol, Carvedilol, Labetalol, Nadolol, Oxprenolol, Penbutolol, Pindolol, Sotalol, Timolol, Acebutolol, Atenolol, Betaxolol, Bisoprolol, Celiprolol, Metoprolol, Nebivolol, Esmolol, Butaxamine, ICI-118,551, SR 59230A, 4-NEMD, 7-Me-marsanidine, Agmatine, Apraclonidine, Brimonidine, Cannabigerol, Clonidine, Detomidine, Dexmedetomidine, Fadolmidine, Guanabenz, Guanfacine, Lofexidine, Marsanidine, Medetomidine, Methamphetamine, Mivazerol, Rilmenidine, Romifidine, Talipexole, Tiamenidine, Tizanidine, Tolonidine, Xylazine, Xylometazoline, L-748,328, L-748,337 and SR 59,230A, Amibegron (SR-58611A), CL-316,243, L-742,791, L-796,568, LY-368,842, Mirabegron (YM-178), Ro40-2148, Solabegron (GW-427,353), and Vibegron (MK-4618); or to administer to the patient a sympathetic ganglionic blocking agent selected from the group consisting of hexamethonium, pentolinium, mecamylamine, trimetaphan, tubocurarine, pempidine, benzohexonium, chlorisondamine, pentamine, and tetra ethylammonium chloride; or to administer to the patient a cholinergic receptor blocking agent selected from the group consisting of atropine, scopolamine, homatropine, tropicamide, benzproine, biperiden, trihexyphenidyl, oxybutynin, tolterodine, solifenacin, dicyclomine, darifenacin, glycopyrrolate, ipratropium, and tiotropium; or to administer the patient with a combination thereof.

### Claim 20

A method for treating epileptic seizures comprising:
administering to a patient a combination of an adrenergic blocking agent and an anti-seizure agent; or a combination of a cholinergic blocking and an anti-seizure agent.

### Claim 21 (depends on 20)

The method of claim 20, wherein:
the adrenergic blocking agent is selected from the group consisting of n-g(fluorenyl)-n ethyl-β chloroethylamine (SKF-501), Phentolamine, Doxazosin, Terazosin, Tamsulosin, Alfuzosin, Phenoxybenzaamine, Yohimbine, Imipramine, Silodosin, Amitriptilyne, Indoramine, Abanoquil, Corynanthine, Ajmalicine, Quetiapine, Dapiprazone, Amoxapine, Risperidone, Idazoxan, Bunazosin, Doxepin, Atiprosin, Piperoxan, Fenmetozole, Denopamine, Dobutamine, Dopexamine, Epinephrine, Isoprenaline, Isoproterenol, Prenalterol, Xamotero, Arformoterol, Buphenine, Clenbuterol, Dopexamine, Epinephrine, Fenoterol, Formoterol, Isoetarine, Levosalbutamol, levalbuterol, Orciprenaline, metaproterenol, Pirbuterol, Procaterol, Ritodrine, Salbutamol, albuterol, Salmeterol, Terbutaline, Arbutamine, Befunolol, Bromoacetylalprenololmenthane, Broxaterol, Cimaterol, Cirazoline, Etilefrine, Hexoprenaline, Higenamine, Isoxsuprine, Mabuterol, Methoxyphenamine, Oxyfedrine, Ractopamine, Reproterol, Rimiterol, Tretoquinol, Tulobuterol, Zilpaterol, Zinterol, Propranolol, Bucindolol, Carteolol, Carvedilol, Labetalol, Nadolol, Oxprenolol, Penbutolol, Pindolol, Sotalol, Timolol, Acebutolol, Atenolol, Betaxolol, Bisoprolol, Celiprolol, Metoprolol, Nebivolol, Esmolol, Butaxamine, ICI-118,551, SR 59230A, 4-NEMD, 7-Me-marsanidine, Agmatine, Apraclonidine, Brimonidine, Cannabigerol, Clonidine, Detomidine, Dexmedetomidine, Fadolmidine, Guanabenz, Guanfacine, Lofexidine, Marsanidine, Medetomidine, Methamphetamine, Mivazerol, Rilmenidine, Romifidine, Talipexole, Tiamenidine, Tizanidine, Tolonidine, Xylazine, Xylometazoline, L-748,328, L-748,337 and SR 59,230A, Amibegron (SR-58611A), CL-316,243, L-742,791, L-796,568, LY-368,842, Mirabegron (YM-178), Ro40-2148, Solabegron (GW-427,353), Vibegron (MK-4618), hexamethonium, pentolinium, mecamylamine, trimetaphan, tubocurarine, pempidine, benzohexonium, chlorisondamine, and pentaamine;
the cholinergic blocking agent is selected from the group consisting of atropine, scopolamine, homatropine, tropicamide, benzproine, biperiden, trihexyphenidyl, oxybutynin, tolterodine, solifenacin, dicyclomine, darifenacin, glycopyrrolate, ipratropium, and tiotropium; and
the anti-seizure agent is selected from the group consisting of phenytoin, carbamazepine, clobazam, divalproex, eslicarbazepine, oxcarbazepine, lacosamide, ethosuximide, gabapentin, methsuxamide, perampanel, phenobarbital, pregabalin, rufinamide, tiagabine, vigabatrin, levetiracetam, clonazepam, clorazepate, ezogabine, felbamate, lamotrigine, lorazepam, primidone, topiramate, valproic acid, and zonisamide.
